Enzon Pharmaceuticals Inc  

(Public, NASDAQ:ENZN)   Watch this stock  
Find more results for ENZN
-0.007 (-0.70%)
Real-time:   11:35AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.97 - 0.99
52 week 0.78 - 1.83
Open 0.99
Vol / Avg. 32,664.00/165,998.00
Mkt cap 44.92M
P/E 1.55
Div/yield 0.10
EPS 0.64
Shares 44.14M
Beta 1.16
Inst. own 61%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 92.99% 52.62%
Operating margin 93.01% 52.65%
EBITD margin - 67.16%
Return on average assets 118.90% 17.54%
Return on average equity 124.65% 43.88%
Employees 1 -
CDP Score - -


United States - Map
+1-732-9804500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company�s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists Survivin and the Androgen Receptor (AR). In addition, it has mRNA antagonist targets in various stages of preclinical research. The Company receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology-PEGINTRON. It is also using LNA technology to develop mRNA antagonists against oncology targets.

Officers and directors

Jonathan N. Christodoro Chairman of the Board
Age: 38
Bio & Compensation  - Reuters
George W. Hebard III Interim Principal Executive Officer and Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Richard L. Feinstein Principal Financial Officer, Vice President - Finance
Age: 70
Bio & Compensation  - Reuters
Odysseas D. Kostas M.D. Director
Age: 39
Bio & Compensation  - Reuters
Jennifer I. McNealey Director
Age: 40
Bio & Compensation  - Reuters